Pharma's New Follow-On Strategy
Executive Summary
For all its noise and parties, speeches, and meetings, the 26th annual JP Morgan Healthcare Conference felt more like an indecisive pause than the industry's first step into the new year. Biotech investors see their best exits through M&A, but activity's been unpredictable and less buoyant than expected. But generics and still-impoverished pipelines will force drug companies to make different choices. The quickest solution to pipeline problems is to imitate biotechs by developing or buying biotech products and technologies. These technologies allow Big Pharma to do with biologics what they used to do with small molecules: create fast-followers. Except that there's far more competition this time around.
You may also be interested in...
Reimbursement: The New Biopharma Investment Hurdle
With a growing number of expensive therapeutics entering the market and rising pressures to contain costs, gauging reimbursement is now a crucial element deal makers must evaluate.
Reimbursement: The New Biopharma Investment Hurdle
With a growing number of expensive therapeutics entering the market and rising pressures to contain costs, gauging reimbursement is now a crucial element deal makers must evaluate.
A Two Pharma Horse Race In Follow-On Biologics
In the horse race to develop follow-on biologics, there are two companies vying for the pole position: Teva Pharmaceutical Industries Ltd. and Merck & Co. Inc. Even as other pharmaceutical companies weigh the merits of building FOB capabilities, these two companies are demonstrating their commitment not just with words but with cold, hard cash.